Objective. The purpose was to explore the clinical effect of Danqi Buxin decoction on chronic heart failure (CHF) with yang deficiency and its effect on cardiac function and life quality of patients. Methods. 106 CHF patients with yang deficiency treated in Jinan Municipal Hospital of Traditional Chinese Medicine from February 2019 to February 2020 were selected as the research objects and divided into the treatment group and reference group according to the odd and even admission numbers, with 53 cases in each group. The reference group was treated with routine antiheart failure drugs, while the treatment group was additionally treated with Danqi Buxin decoction to compare the clinical effect and cardiac function changes between the two groups. Results. The clinical effective rate in the treatment group was significantly higher than that in the reference group P < 0.05 . The TCM symptom scores at T1, T2, and T3 in the treatment group were significantly higher than those in the reference group P < 0.05 . After treatment, the LVEDV levels in both groups were significantly higher than those before treatment, while the BNP levels were significantly lower than those before treatment P < 0.001 . The LVEDV level in the treatment group after treatment was higher than that in the reference group, while the BNP level in the treatment group was significantly lower than that in the reference group P < 0.001 . The life quality scores in the treatment group after treatment were significantly higher than those in the reference group P < 0.05 . Conclusion. Danqi Buxin decoction on the basis of conventional drugs can significantly improve the cardiac function and life quality of CHF patients with yang deficiency type. Its further research is helpful to establish a good treatment plan for CHF patients.

Objective. The main objective is to investigate the effect of Yifei-Huoxue decoction combined with tiotropium on the inflammatory cytokine levels, pulmonary function, and quality of life in patients with chronic obstructive pulmonary disease (COPD). Methods. Ninety-eight COPD patients who were treated in our hospital from January 2021 to January 2022 were selected as the research objects, and they were divided into reference group (routine treatment) and study group (Yifei-Huoxue decoction combined with tiotropium), with 49 cases in each group. The patients’ clinical indexes were compared between the two groups, and the clinical efficacy in the two groups was analyzed. Results. Compared with the reference group, the study group had remarkably lower inflammatory cytokine levels (including tumor necrosis factor- α (TNF- α ), C-reactive protein (CRP), and interleukin-6 (IL-6)) after treatment P > 0.05 . In terms of the patients’ pulmonary function indexes after treatment, the study group achieved lower forced vital capacity (FVC), forced expiratory volume in 1s (FEV1), and FEV1/FVC levels compared with the reference group P < 0.05 . Both groups had a lower erythrocyte sedimentation rate (ESR) after treatment compared with that before treatment. However, the intergroup difference in the ESRs after treatment was remarkable, and the study group had a much lower ESR compared with the reference group (P < 0.05). Compared with the reference group, the study group achieved much higher 36-item short form health survey (SF-36) scores in dimensions of general health, physical functioning, social functioning, and mental health after treatment (P < 0.05). Conclusion. Yifei-Huoxue decoction combined with tiotropium not only enhances the COPD patients’ pulmonary function but also decreases their inflammatory levels. Therefore, this treatment is conducive to promoting the COPD patients’ recovery and exerts positive effect on improving their quality of life.